Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

6.35

-0.12

-1.85%

盘后6.49

+0.14+2.27%

19:50 EST

High6.55	Low6.16	Vol1.41M
Open6.47	D1 Closing6.47	Amplitude6.03%
Mkt Cap348.60M	Tradable Cap288.79M	Total Shares54.90M
T/O9.07M	T/O Rate3.11%	Tradable Shares45.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":6.35,"timestamp":1765573200000,"preClose":6.47,"halted":0,"volume":1414832,"hourTrading":{"tag":"盘后","latestPrice":6.4939,"preClose":6.35,"latestTime":"19:50 EST","volume":5655,"amount":35999.0097,"timestamp":1765587045192},"delay":0,"floatShares":45478500,"shares":54898303,"eps":-0.472894,"marketStatus":"Market Closed","change":-0.12,"latestTime":"12-12 16:00:00 EST","open":6.474,"high":6.55,"low":6.16,"amount":9069661.124179201,"amplitude":0.060278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.472894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":6.47,"preHourTrading":{"tag":"盘前","latestPrice":6.55,"preClose":6.47,"latestTime":"09:28 EST","volume":10311,"amount":67379.9794437,"timestamp":1765549680080},"postHourTrading":{"tag":"盘后","latestPrice":6.4939,"preClose":6.35,"latestTime":"19:50 EST","volume":5655,"amount":35999.0097,"timestamp":1765587045192},"volumeRatio":0.9728180915787661,"impliedVol":1.2435,"impliedVolPercentile":0.628},"requestUrl":"/m/hq/s/CADL","defaultTab":"news","newsList":[{"id":"2590110530","title":"Candel Therapeutics Showcases Advances in Immune-Based Cancer Therapies in New Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590110530","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590110530?lang=en_us&edition=fundamental","pubTime":"2025-12-11 04:29","pubTimestamp":1765398576,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDLp5lhW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CADL"],"gpt_icon":0},{"id":"2589356233","title":"Candel Therapeutics Price Target Maintained With a $15.00/Share by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2589356233","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589356233?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:09","pubTimestamp":1765202940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 09:09 ET (14:09 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"gpt_icon":0},{"id":"2584922898","title":"Candel Therapeutics Q3 Net Income USD -11.269 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584922898","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584922898?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:37","pubTimestamp":1763573867,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Candel Therapeutics Q3 income from operations USD -13.207 million vs. IBES estimate USD -11.8 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202513:21:00.117 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD8Kk4jB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"gpt_icon":0},{"id":"2584767174","title":"Candel Therapeutics Hosts Virtual R&D Event Showcasing Immunotherapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2584767174","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584767174?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:05","pubTimestamp":1763413510,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Inc. will host a virtual Research and Development Event on December 5, 2025. The event will feature presentations on the company's viral immunotherapy approach, updates on its oncology-focused pipeline, and specific sessions on CAN-2409 for newly diagnosed localized prostate cancer, the roadmap to a Biologics License Application, and pre-commercialization plans. The event will also include a panel discussion on the next wave of innovation in immuno-oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbz08bb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4588","BK4539","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","CADL","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2583368912","title":"Candel Therapeutics Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2583368912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583368912?lang=en_us&edition=fundamental","pubTime":"2025-11-15 04:07","pubTimestamp":1763150820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 15:07 ET (20:07 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"gpt_icon":0},{"id":"2583087895","title":"Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583087895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583087895?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:55","pubTimestamp":1763121347,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics today and set a price target of $25.00. Newman covers the Heal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-candel-therapeutics-cadl-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-candel-therapeutics-cadl-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"gpt_icon":0},{"id":"2583708025","title":"Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583708025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583708025?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:16","pubTimestamp":1763119002,"startTime":"0","endTime":"0","summary":"In a report released today, Alec Stranahan from Bank of America Securities reiterated a Hold rating on Candel Therapeutics, with a price target of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-hold-rating-for-candel-therapeutics-cadl-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-hold-rating-for-candel-therapeutics-cadl-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","CADL"],"gpt_icon":0},{"id":"2583652309","title":"Candel Therapeutics Advances Cancer Therapies with Strong Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2583652309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583652309?lang=en_us&edition=fundamental","pubTime":"2025-11-14 12:39","pubTimestamp":1763095179,"startTime":"0","endTime":"0","summary":"Candel Therapeutics, Inc. ( ($CADL) ) has released its Q3 earnings. Here is a breakdown of the information Candel Therapeutics, Inc. presented to i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-advances-cancer-therapies-with-strong-q3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-advances-cancer-therapies-with-strong-q3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CADL","BK4539"],"gpt_icon":0},{"id":"2583935225","title":"Candel Therapeutics Showcases Progress of CAN-2409 and Pipeline Advancements in Cancer Immunotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2583935225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583935225?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:33","pubTimestamp":1763040815,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Inc. has released a corporate presentation detailing recent progress across its oncology pipeline. The company highlighted positive clinical data for its lead asset, CAN-2409, an off-the-shelf therapy aimed at generating individualized anti-cancer immune responses in multiple solid tumor types. Notably, CAN-2409 demonstrated positive overall survival data in randomized phase 2a trials for both borderline resectable pancreatic cancer and therapy-resistant non-small cell lung cancer, as well as positive outcomes in a phase 3 trial for localized, intermediate-to-high-risk prostate cancer. The presentation also provided updates on CAN-3110, an oncolytic HSV-1 therapy designed for tumor-specific replication, which has shown proof of concept in recurrent high-grade glioma. The company reported cash and cash equivalents of $87.2 million as of September 30, 2025, and outlined pre-commercialization activities for CAN-2409. Intellectual property protection and regulatory desi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4RCtTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"gpt_icon":0},{"id":"2583520593","title":"Candel Therapeutics Q3 net loss widens to $11.3 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583520593","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583520593?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:33","pubTimestamp":1763040791,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Q3 net loss widens to $11.3 mlnOverviewCandel Therapeutics reports Q3 net loss of $11.3 mln, increased from last yearCompany secures $130 mln loan facility with Trinity Capital to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0JZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4539","BK4139"],"gpt_icon":0},{"id":"2583598051","title":"BRIEF-Candel Therapeutics Q3 Net Income USD -11.269 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598051","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598051?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:25","pubTimestamp":1763040345,"startTime":"0","endTime":"0","summary":"BRIEF-Candel Therapeutics Q3 Net Income USD -11.269 Million\n\n\nNov 13 (Reuters) - Candel Therapeutics Q3 income from operations USD -13.207 million vs. IBES estimate USD -11.8 million.\n\nQ3 basic EPS USD -0.21\nQ3 operating expenses USD 13.207 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXA51834:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"gpt_icon":0},{"id":"2583707598","title":"Candel Therapeutics Q3 Basic EPS USD -0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583707598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583707598?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:25","pubTimestamp":1763040300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXA51834:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CADL","BK4139"],"gpt_icon":0},{"id":"2583659870","title":"Candel Therapeutics Q3 Income From Operations USD -13.207 Million VS. Ibes Estimate USD -11.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583659870?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:25","pubTimestamp":1763040300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXA51834:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"gpt_icon":0},{"id":"2583980455","title":"Candel Therapeutics Inc: Expect Phase 2 Nsclc Long-Term Survivor Data in Q1 2026 and Phase 3 Initiation in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980455?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:23","pubTimestamp":1763040234,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP11H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CADL","BK4539"],"gpt_icon":0},{"id":"2583598709","title":"Candel Therapeutics Inc Qtrly Net Loss per Share $0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598709?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:23","pubTimestamp":1763040234,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WP11H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4539","BK4139"],"gpt_icon":0},{"id":"2580049730","title":"Candel Therapeutics announces it will deliver three presentations at SITC","url":"https://stock-news.laohu8.com/highlight/detail?id=2580049730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580049730?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:10","pubTimestamp":1762265459,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) announced it will deliver three presentations at the Society for Immunotherapy of Cancer, SITC, 40th Anniversary Annual ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-announces-it-will-deliver-three-presentations-at-sitc-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-announces-it-will-deliver-three-presentations-at-sitc-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4139","BK4539"],"gpt_icon":0},{"id":"2580737024","title":"Candel Therapeutics Announces Positive Phase 3 Results for CAN-2409 in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737024","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580737024?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:00","pubTimestamp":1762264857,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Inc. announced that it will deliver three presentations at the Society for Immunotherapy of Cancer  40th Anniversary Annual Meeting, taking place November 5-9, 2025. Among the highlights, the company will present positive phase 3 clinical trial data for CAN-2409 in newly diagnosed, localized prostate cancer, which achieved its primary endpoint and was supported by secondary endpoints. The company plans to submit a Biologics License Application  for CAN-2409 in prostate cancer in the fourth quarter of 2026. Additional presentations will cover multi-omics analysis of CAN-2409 in non-small cell lung cancer and preclinical validation of the enLIGHTEN Discovery Platform in a breast cancer model. Results from these studies will be presented at the SITC 2025 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLbyypQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","BK4539","BK4112","BK4588","CADL","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","BK4585"],"gpt_icon":0},{"id":"2580132802","title":"Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London","url":"https://stock-news.laohu8.com/highlight/detail?id=2580132802","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580132802?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:05","pubTimestamp":1762175100,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biolog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179246/0/en/Candel-Therapeutics-to-Present-at-Jefferies-Global-Healthcare-Conference-in-London.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4526","BK4139","BK4595","CAN","BK4600","XLV","BK4107","XBI","L","LU0128526141.USD","LU0210528500.USD","CADL","BK4539","BK4585","LU0053666078.USD","BK4137","BK4170","LU0029874061.USD","BK4588","BK4581","HCSG","LU2487616109.SGD"],"gpt_icon":0},{"id":"2578554529","title":"Stephens Initiates Candel Therapeutics at Overweight With $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2578554529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578554529?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:38","pubTimestamp":1761651523,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) has an average rating of buy and mean price target of $18.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CADL"],"gpt_icon":0},{"id":"2578932659","title":"Candel Therapeutics Initiated at Overweight by Stephens & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2578932659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578932659?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:22","pubTimestamp":1761646920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CADL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 06:22 ET (10:22 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":0.1914},{"period":"1month","weight":0.2907},{"period":"3month","weight":0.3257},{"period":"6month","weight":0.2378},{"period":"1year","weight":-0.352},{"period":"ytd","weight":-0.2684}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.079266},{"month":2,"riseRate":0.5,"avgChangeRate":0.090279},{"month":3,"riseRate":0.25,"avgChangeRate":-0.133894},{"month":4,"riseRate":0.25,"avgChangeRate":0.747487},{"month":5,"riseRate":1,"avgChangeRate":0.149002},{"month":6,"riseRate":0,"avgChangeRate":-0.170269},{"month":7,"riseRate":0.25,"avgChangeRate":0.011025},{"month":8,"riseRate":0.8,"avgChangeRate":0.068985},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01705},{"month":10,"riseRate":0.4,"avgChangeRate":-0.110246},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.317783}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction